SCHEMBL30355772

SCHEMBL30355772

Cc1ccccc1-c1noc(-c2ccc3c(c2)nnn3C2CC2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.58
S1PR1 P21453 3/20 0.52
S1PR5 Q9H228 1/20 0.52
NPC1 O15118 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 3/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
PKM P14618 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NR1H4 Q96RI1 3/20 0.48
TP53 P04637 3/20 0.46
GAA P10253 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523843 1.00 GRM5 (0.58) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL30355644 0.96 GRM5 (0.64) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL30355675 0.96 GRM5 (0.61) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL23524142 0.96 GRM5 (0.64) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL23524110 0.96 GRM5 (0.61) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL23524054 0.95 GRM5 (0.63) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL30355398 0.95 GRM5 (0.63) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL23524052 0.94 GRM5 (0.54) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL30355463 0.94 GRM5 (0.54) GRM5S1PR1S1PR5NPC1SMN1; SMN2
SCHEMBL23523919 0.88 GRM5 (0.59) GRM5S1PR1S1PR5NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 US disclosed
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 US disclosed
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME TREVENA, INC. 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 GRM5 456/4885S1PR1 1/4885S1PR5 4/4885
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME S1PR1, S1PR2, S1PR3 GRM5 71/4885S1PR1 1/4885S1PR5 4/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 GRM5 456/4885S1PR1 1/4885S1PR5 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.